Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

econd quarter of 2010, primarily due to higher non-GAAP profit from operations, which was partially offset by lower other income.  

Diluted earnings per ADS were $0.18, which compares with $0.26 in the second quarter of 2010.  

Non-GAAP diluted earnings per ADS were $0.25, which compares with $0.28 in the second quarter of 2010.

Financial Position  As of June 30, 2011, the Company had cash and cash equivalents of $41.6 million and short term debt of $0.8 million. During the quarter, capital expenditures totaled $11.0 million, including $5.5 million related to the purchase of a 68,000 square foot new lab and office building which replaced the original 36,000 square foot facility in Chengdu. The purchased lab and office building allows us to reduce overall expenditures and improve our earnings over time.  With a strong balance sheet and sound financial position, the Company is well positioned to make targeted investments when opportunities arise.  

Full Year 2011 GuidanceThe Company reconfirms its guidance for full year 2011.  The Company expects:

  • Net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010.  
  • Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010.
  • Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.

  • This reflects the Company's current view and is subject to change.

    Conference CallShangPharma will host a conference call and live webcast at 8am New York time on August 22, 2011 (8pm Beijing time on August 22, 2011).  A PowerPoint presentation accompanying the prepared remarks will be available on the Company's website shortly before the call.  

    The dial-in details
    '/>"/>

    SOURCE ShangPharma Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
    2. ShangPharma Announces First Quarter 2011 Results
    3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
    4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
    5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
    6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
    7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
    8. Neurologix Announces Second Quarter 2011 Financial Results
    9. Bion Announces New U.S. Patent for Phosphorus Removal
    10. ViaCyte Announces Executive Management Changes
    11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
    (Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
    (Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
    (Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) ... Therapy Market Outlook 2020 " report to their ... and regenerative medicine is expected to have huge marketing ... help in the growth of deregulated organs. Several therapeutic ... unable to form new tissue or sometimes organ transplant ...
    Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
    ... from the medical community in Europe and the U.S. examined ... disease and sepsis, and in cardiac surgery, during CSL ... in Clinical Fluid Management ." (Logo: ... frank and provocative exchange about the uses and effectiveness of ...
    ... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ) ... of Pathology & Laboratory Medicine, University of Pennsylvania, and ... been elected a fellow in the American Association for ... the "father of synthetic DNA vaccines," is being honored ...
    ... Researchers at Northwestern University have developed a new ... could be a step toward the creation of ... its many promising attributes, graphene is a one-atom ... strength and conductivity. Among graphene,s many possible applications ...
    Cached Biology Technology:Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 2Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 3Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 2Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 3Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 4A step toward better electronics 2
    (Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
    (Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
    (Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
    Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
    ... CORVALLIS, Ore. Researchers at Oregon State University for the ... overfishing and nitrate pollution can help destroy coral reefs ... bring with it unwanted pathogens, choke off oxygen and disrupt ... big enough to essentially smother corals. They can get out ...
    ... who take the time to read food labels are ... from a recently released study authored by Steven T. ... of Agriculture,s Department of Agricultural and Resource Economics, in ... Compostela in Spain, the University of Arkansas and the ...
    ... press release is available in Spanish . ... Development, NEIKER-Tecnalia, and the National Institute of Agricultural Research in ... of ,black dead arm, (BDA) on grapevine leaves are, in ... and BDA are diseases that affect the trunk of ...
    Cached Biology News:The 'slippery slope to slime': Overgrown algae causing coral reef declines 2NEIKER and INRA discover that BDA symptoms in grapevine leaves are a sign of esca 2
    ...
    ... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... acids 178-227 of human YBX2. ... is proprietary). ...
    ... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
    ... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
    Biology Products: